title: Application of Medicare's New Technology Add-on Payment Program for Blinatumomab.
authors.affiliation: Robert Wood Johnson Foundation Clinical Scholars Program, Yale University School of Medicine, New Haven, Connecticut2Department of Internal Medicine, Connecticut Veterans Affairs Health System, West Haven, Connecticut.
authors.forename: Sanket S
authors.initials: SS
authors.lastname: Dhruva
authors.affiliation: Division of Hematology-Oncology, Knight Cancer Institute, Department of Public Health and Preventive Medicine, Oregon Health and Sciences University, Portland.
authors.forename: Vinay
authors.initials: V
authors.lastname: Prasad
mesh_terms: D018033:Antibodies, Bispecific / Q000008:administration & dosage / Q000191:economics* / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000191:economics* / Q000627:therapeutic use*; D003362:Cost-Benefit Analysis; D004334:Drug Administration Schedule; D016527:Drug Costs / Q000331:legislation & jurisprudence; D006297:Health Services Accessibility / Q000191:economics; D006801:Humans; D007262:Infusions, Intravenous; D007349:Insurance, Health, Reimbursement / Q000191:economics* / Q000331:legislation & jurisprudence; D006278:Medicare / Q000191:economics* / Q000331:legislation & jurisprudence; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000175:diagnosis / Q000188:drug therapy* / Q000191:economics*; D013997:Time Factors; D016896:Treatment Outcome; D014481:United States
chemical_list: D018033:Antibodies, Bispecific; D000970:Antineoplastic Agents; C510808:blinatumomab